Tepezza Lawsuit
Tepezza (teprotumumab-trbw) is an infused biologic approved by the FDA in January 2020 to treat thyroid eye disease. It was developed by Horizon Therapeutics, which Amgen acquired in October 2023. For many patients Tepezza meaningfully improved eye bulging and double vision — but a growing number reported something else: ringing in their ears and hearing loss that did not go away.
Why Are Tepezza Lawsuits Being Filed?
Plaintiffs allege that Horizon knew from clinical trial data and post-marketing reports that Tepezza could cause permanent sensorineural hearing loss and tinnitus, but failed to adequately warn patients and physicians. The original 2020 label listed hearing issues only in passing; it was not until July 2023 that the FDA required updated labeling directing physicians to assess patients’ hearing before, during, and after treatment. Plaintiffs argue that earlier, stronger warnings would have allowed hearing monitoring and informed treatment decisions. The defendants deny the allegations.
MDL 3079: Where the Litigation Stands
In June 2023, federal Tepezza lawsuits were consolidated into MDL 3079 in the U.S. District Court for the Northern District of Illinois before Judge Thomas M. Durkin, with roughly 275 cases pending as of mid-2026. Fact discovery closed in 2025, expert work followed, and in October 2025 the court struck all bellwether deadlines after off-the-record discussions with counsel — a development widely read as a sign of serious settlement negotiations. Bellwether trial dates have since been reset, with the first currently slated for August 2026. No settlement has been publicly announced.
Injuries in the Tepezza Litigation
The litigation centers on permanent or long-lasting hearing damage: sensorineural hearing loss, tinnitus (persistent ringing), a feeling of ear fullness or muffled hearing, and hearing loss requiring hearing aids. Injuries typically emerged during or shortly after a course of Tepezza infusions.
Who May Qualify?
You may qualify for a free case review if you received Tepezza infusions for thyroid eye disease and developed hearing loss or tinnitus during or after treatment. Infusion records and audiology or ENT records documenting the hearing damage are the key evidence. Statutes of limitations vary by state and are expiring in some states for patients treated in 2020–2022, so prompt review matters.